On September 13, 2024 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported the company and its research collaborators will present data from several studies utilizing Guardant technology to advance precision oncology at the European Society for Medical Oncology Congress (ESMO) (Free ESMO Whitepaper) in Barcelona, Spain, Sept. 13-17, 2024 (Press release, Guardant Health, SEP 13, 2024, View Source [SID1234646602]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Data on the Guardant Reveal minimal residual disease test in locally advanced rectal cancer patients enrolled in the NO-CUT trial will be presented in a proffered paper session during Presidential Symposium III. Other presentations will include findings from studies evaluating Guardant360 for therapy selection in advanced breast cancer and other solid tumors, and the Guardant Infinity platform for response monitoring in advanced non-small cell lung cancer (NSCLC).
"Our latest data featured at ESMO (Free ESMO Whitepaper) further highlight the value of Guardant’s technology in precision oncology and the critical role liquid biopsy can play in informing therapy selection and treatment management across multiple tumor types," said Craig Eagle, M.D., chief medical officer at Guardant Health. "We look forward to sharing how Guardant tests can contribute to improved outcomes across all stages of cancer care."
Complete list of Guardant Health and collaborator presentations at ESMO (Free ESMO Whitepaper) 2024
Abstract
Title (Hall 6, unless otherwise noted)
Product
Saturday, September 14 | 9:00 – 17:00
1295P
EP0031 a next-generation selective RET inhibitor (SRI): Correlation of molecular and clinical responses in patients with RET alteration positive solid tumours naïve to or following prior SRI
Guardant Infinity
Sunday, September 15 | 9:00 – 17:00
127P
Clinical utility of circulating tumor DNA (ctDNA) next generation sequencing (NGS) to inform treatment decisions for patients (pts) with advanced solid tumors
Guardant 360
Monday, September 16 | 9:00 – 17:00
418P
Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer
Guardant 360
419P
Prevalence of gene rearrangement on ctDNA NGS and its targetability in patients with advanced breast cancer
Guardant 360
Monday, September 16 | 17:04 – 17:16
509O
Total neoadjuvant treatment (TNT) with non-operative management (NOM) for proficient mismatch
repair locally advanced rectal cancer (pMMR LARC): first results of NO-CUT Trial
Proffered Paper Session: Presidential Symposium III: Eyes to the future, Barcelona Auditorium, Hall 2
Guardant Reveal
The full abstracts for Guardant Health and a list of all abstracts being presented at the ESMO (Free ESMO Whitepaper) Congress can be found on the ESMO (Free ESMO Whitepaper) website.
For information and updates from the conference, follow Guardant Health on LinkedIn, X (Twitter) and Facebook or visit Guardant on-site at booth #510.